Methylenecyclopropane nucleosides have been reported to be active against many of the human herpesviruses. The most active compound of this class is cyclopropavir (CPV), which exhibits good antiviral activity against human cytomegalovirus (HCMV), Epstein-Barr virus, both variants of human herpesvirus 6, and human herpesvirus 8. CPV has two hydroxymethyl groups on the methylenecyclopropane ring, but analogs with a single hydroxymethyl group, such as the prototypical (S)-synguanol, are also active and exhibit a broader spectrum of antiviral activity that also includes hepatitis B virus and human immunodeficiency virus. Here, a large set of monohydroxymethyl compounds with ether and thioether substituents at the 6 position of the purine was synthesized and evaluated for antiviral activity against a range of human herpesviruses. Some of these analogs had a broader spectrum of antiviral activity than CPV, in that they also inhibited the replication of herpes simplex viruses 1 and 2 and varicellazoster virus. Interestingly, the antiviral activity of these compounds appeared to be dependent on the activity of the HCMV UL97 kinase but was relatively unaffected by the absence of thymidine kinase activity in HSV. These data taken together indicate that the mechanism of action of these analogs is distinct from that of CPV. They also suggest that they might be useful as broad-spectrum antiherpesvirus agents and may be effective in the treatment of resistant virus infections.
T
he human herpesviruses are endemic in the human population, with the seroprevalence of some, such as the B variant of human herpesvirus 6 (HHV-6B), approaching 100% in the first years of life. Each of these viruses establishes lifelong latent or persistent infections and can initiate subsequent episodes of disease, although they are typically minor and self-limiting when held in check by the host's competent immune system. One feature common among all these herpesviruses is the progression to severe life-threatening disease in immunocompromised hosts (1) (2) (3) (4) .
Approved therapies for herpesviruses in the United States include (i) acyclovir (ACV) and its prodrug, valacyclovir, for the therapy of herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), and varicella-zoster virus (VZV) infections, (ii) famciclovir for the therapy of HSV-1, HSV-2, and VZV infections, (iii) ganciclovir (GCV), its prodrug, valganciclovir, and cidofovir (CDV) for the therapy of human cytomegalovirus (HCMV) infections, and (iv) foscarnet (PFA) for the therapy of HSV and HCMV infections. Infections in immunocompromised hosts can often become resistant to initial therapies (5, 6) , and secondary therapies, such as CDV and PFA, are associated with dose-limiting toxicities (7) . Additional therapies are required not only to treat resistant infections but also for use in combination therapy in high-risk populations (8, 9) .
A host of methylenecyclopropane nucleoside (MCPN) analogs have been shown to be active against many of the herpesviruses in cell culture and animal model infections; this body of work was recently reviewed by Jiri Zemlicka (10) . Earlier MCPN analogs had a single hydroxymethyl group on the cyclopropane ring that is thought to mimic the 5= hydroxyl moiety in deoxyribonucleosides (11) . This series of compounds is similar to ACV, in that once the compound is incorporated into DNA, further strand elongation is impossible because of the lack of a counterpart to the 3= hydroxy group. The newer analogs are dihydroxymethyl derivatives and are similar to GCV, in that there is a second hydroxyl group that might be recognized by the DNA polymerase and utilized for further strand elongation (12) . The most active compound of this class is cyclopropavir (CPV), which exhibits good antiviral activity against HCMV, murine CMV (MCMV), Epstein-Barr virus (EBV), both variants of HHV-6, and HHV-8 (12, 13) . Oral administration of this compound to mice infected with MCMV reduced both viral replication in the organs and mortality (14) . It was also shown to be effective against HCMV replication in human fetal tissue implanted into SCID mice.
The spectrum of antiviral activity of monohydroxymethyl compounds, as typified by (S)-synguanol, is broader than that of dihydroxymethyl analogs, and some analogs inhibit HCMV, MCMV, EBV, HHV-6, hepatitis B virus, and human immunodeficiency virus (15) (16) (17) . A few analogs even had some antiviral activity against HSV-1, HSV-2, and VZV. Two of the monohydroxymethyl MCPNs, synguanol and synadenol, significantly reduced mortality and virus replication in mice infected with MCMV (18) . Some derivatives of (S,Z)-2-aminopurine in this series with ether and thioether substituents at the 6 position that were reported to be active against HCMV and MCMV also exhib-ited detectable activity against HSV-1, HSV-2, VZV, and hepatitis B virus (19) . Recently, a large set of dihydroxymethyl analogs with 6-ether and -thioether moieties have also been reported to be active against some of the herpesviruses (20) . A similar set of compounds in the monohydroxymethyl series was synthesized and evaluated for antiviral activity against the herpesviruses (see Tables 1 to 4 for antiviral activities). Compounds 2c, 2d, 2f, and 3b were published previously and were used to help validate the synthesis and biological activity of the current results (19) . Significantly, some analogs exhibited good antiviral activity against all the herpesviruses tested, including the alphaherpesviruses. The antiviral activity of these compounds also appeared to be dependent on the activity of the HCMV UL97 kinase but was relatively unaffected by the absence of thymidine kinase (TK) activity in HSV. These data suggest that some of the compounds might be useful as broad-spectrum antiherpesvirus agents in immunocompromised hosts. Compounds such as these might be particularly valuable since they appear to be effective against drug-resistant isolates of HCMV and HSV that are common in this population.
MATERIALS AND METHODS
Synthesis of methylenecyclopropane nucleosides. The first monohydroxymethyl methylenecyclopropane nucleosides were synthesized using a modification of the procedure utilized by Zemlicka and colleagues (19) , as outlined in the supplemental material and Fig. 1 . The common intermediate compound 1 was prepared according to the previously reported chiral synthesis method (20) . This intermediate was then treated with either an alkoxide to produce the ether series compounds 2a to 2j or a thiolate to produce thioether series compounds 3a to 3h in moderate yield. Previous studies have shown that the Z-methylenecyclopropane nucleosides are more active than the corresponding E-isomers (15) and that the S-enantiomers also retain the highest antiherpesvirus activity (15, 16) . Thus, we have focused the current study strictly on the chiral (S,Z)-2-aminopurine methylenecyclopropane nucleosides. Specific details for the synthesis of each compound are provided in the supplemental material.
Reference compounds. Cidofovir was kindly provided by Gilead, Inc., Foster City, CA; ACV and GCV were purchased from the University of Alabama Hospital Pharmacy, and foscarnet (PFA) was purchased from Sigma (St. Louis, MO). The names of the compounds, their abbreviations, and their chemical structures are shown in Tables 1 and 2 . Cells culture and virus strains. Human foreskin fibroblast (HFF) cells were prepared from human foreskin tissue obtained from the University of Alabama at Birmingham tissue procurement facility with approval from its institutional review board. The tissue was incubated at 4°C for 4 h in cell culture medium consisting of minimum essential media (MEM) with Earle's salts supplemented with 10% fetal bovine serum (FBS; HyClone, Inc., Logan, UT) and standard concentrations of L-glutamine, amphotericin B (Fungizone), and vancomycin. Tissue was then placed in phosphate-buffered saline (PBS), minced, rinsed to remove the red blood cells, and resuspended in trypsin-EDTA solution. The tissue suspension was incubated at 37°C and gently agitated to disperse the cells, which were then collected by centrifugation. Cells were resuspended in 4 ml medium, placed in a 25-cm 2 tissue culture flask, and incubated at 37°C in a humidified CO 2 incubator for 24 h. The medium was then replaced with fresh medium, and the cell growth was monitored daily until a confluent cell monolayer was formed. The HFF cells were then expanded through serial passages in standard growth medium of MEM with Earle's salts supplemented with 10% FBS, L-glutamine, penicillin, and gentamicin. The cells were routinely passaged and used for assays at or before passage 10 (21) .
Akata cells were kindly provided by John Sixbey (Louisiana State University, Baton Rouge, LA). HSB-2 cells and BCBL-1 cells were obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. Molt-3 cells were obtained from Scott Schmid at the Centers for Disease Control and Prevention, Atlanta, GA. All lymphocyte cultures were routinely maintained in RPMI 1640 (Mediatech, Inc., Herndon, VA) with 10% FBS, L-glutamine, and antibiotics and passaged twice a week, as described previously (22, 23) . Vero cells were obtained from the American Type Culture Collection (ATCC; Manassas, VA) and were maintained in standard growth medium of MEM with Earle's salts supplemented with 10% FBS, L-glutamine, penicillin, and streptomycin.
The E-377 and DM2.1 strains of HSV-1 as well as the MS and 13078 strains of HSV-2 were characterized as reported previously (24) . HSV-1 strain F was obtained from ATCC. The HCMV strains AD169 and Merlin were obtained from ATCC (Manassas, VA), and C8805/37-1-1 and 759RD100 were gifts of Karen Biron. VZV strain Ellen was obtained from ATCC. Akata cells latently infected with EBV were obtained from John Sixbey. The GS strain of HHV-6A was obtained through the NIH AIDS Research and Reference Reagent Program. The Z29 strain of HHV-6B was a gift of Scott Schmid at the Centers for Disease Control and Prevention, Atlanta, GA. HHV-8 was obtained as latently infected BCBL-1 cells through the NIH AIDS Research and Reference Reagent Program. Antiviral assays. Each experiment that evaluated the antiviral activity of the compounds included both positive-and negative-control compounds to ensure the performance of each assay. Concurrent assessment of cytotoxicity was also performed for each study at equivalent levels of compound exposure. When sufficient material was available, multiple assays were performed for each compound evaluation to obtain statistical data.
(i) Plaque reduction assays for HSV-1, HSV-2, VZV, and HCMV. Monolayers of HFF cells were prepared in six-well plates and incubated at 37°C for 2 days to allow the cells to reach confluence. The medium was then aspirated from the wells, and 0.2 ml of virus was added to each of three wells to yield 20 to 30 plaques in each well. The virus was allowed to adsorb to the cells for 1 h, and the plates were rocked gently every 15 min to redistribute the medium. Compounds were diluted in maintenance cell culture medium consisting of MEM with Earle's salts supplemented with 2% FBS, L-glutamine, penicillin, and gentamicin. Solutions ranging from 300 M to 0.1 M were added to duplicate wells, and the plates were incubated for various times, depending on the virus used. The plaque reduction assay with HSV-1 strain F was performed in a similar manner but with Vero cells infected 1 day after plating. The final FBS concentration in this assay was 5%. For HSV-1 and -2, the monolayers were stained with 1% crystal violet in 20% methanol, and the unbound dye was removed by washing with distilled H 2 O. For assays with HCMV and VZV, the cell monolayer was stained with 1% neutral red solution for 4 h, and then the stain was aspirated and the cells were washed with PBS. For all assays, plaques were enumerated using a stereomicroscope, and the concentration of compound that reduced plaque formation by 50% (50% effective concentration [EC 50 ]) was interpolated from the experimental data.
(ii) Plaque reduction assays for MCMV. Mouse embryo fibroblast cells were prepared from mouse embryos using a procedure similar to that outlined above for HFF cells. The cells were then suspended in tissue culture medium as described above, seeded into 12-well plates, and incubated at 37°C for 24 h. The medium was aspirated, and the cell monolayers were infected with the Smith strain of MCMV in a final volume of 0.2 ml in each of triplicate wells. The infected cells were then incubated at 37°C for 1 h, and the plates were occasionally rocked to ensure that the medium covered the entire monolayer. Compounds were serially diluted 1:5 in the tissue maintenance cell culture medium described above, and the solutions were added to the infected monolayers. Infected monolayers were incubated for 7 days and then stained with 2 ml of a 1% neutral red solution as described above. Plaques were enumerated, and EC 50 s were interpolated from the experimental data by standard methods.
(iii) DNA hybridization assays for EBV, HHV-6A, and HHV-6B. Assays for EBV were performed in Akata cells that were induced to undergo a lytic infection with 50 g/ml of a goat anti-human IgG antibody by methods reported previously (22) . Experimental compounds were diluted in round-bottom 96-well plates to yield concentrations ranging from 20 to 0.016 M. Akata cells were added to the plates at a concentration of 4 ϫ 10 4 cells per well and incubated for 72 h. For HHV-6 assays, compounds were serially diluted in 96-well plates, and then 1 ϫ 10 4 uninfected HSB-2 or Molt-3 cells were added to each well. Infection was initiated by adding HHV-6A-infected HSB-2 cells or HHV-6B-infected Molt-3 cells at a ratio of approximately 1 infected cell for every 10 uninfected HSB-2 cells or Molt-3 cells, respectively, and cells were incubated for 7 days at 37°C.
For all assays, 100 l of denaturation buffer (1.2 M NaOH, 4.5 M 80 NaCl) was added to each well to denature the DNA, and a 50-l aliquot was aspirated through an Immobilon nylon membrane (Millipore, Bedford, MA) using a Biodot apparatus (Bio-Rad, Hercules, CA). The membranes were then allowed to dry before equilibration in DIG Easy Hyb solution (Roche Diagnostics, Indianapolis, IN) at 56°C for 30 min. Specific digoxigenin (DIG)-labeled probes were prepared for each virus according to the manufacturer's protocol (Roche Diagnostics). For EBV, primers 5=-CCC AGG AGT CCC AGT AGT CA-3= and 5=-CAG TTC CTC GCC TTA GGT TG-3= amplified a fragment corresponding to coordinates 96802 to 97234 in the EBV genome (accession number AJ507799). A specific HHV-6 DIG-labeled probe was prepared using primers 5=-CCT TGA TCA TTC GAC CGT TT-3= and 5=-TGG GAT TGG GAT TAG AGC TG-3= to amplify a segment of ORF2 (coordinates 37820 to 38418 in the sequence with accession number X83413). Membranes with EBV DNA were hybridized overnight at 56°C, followed by sequential washes in 0.2ϫ SSC (where 1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate) with 0.1% SDS and 0.1ϫ SSC with 0.1% SDS at the same temperature. For HHV-6A and HHV-6B blots, the probe was allowed to hybridize overnight at 42°C, and the blots were rinsed at the same temperature with 0.2ϫ SSC with 0.1% SDS and 0.1ϫ SSC with 0.1% SDS. Detection of specifically bound DIG probe was performed with anti-DIG antibody using the manufacturer's protocol (Roche Diagnostics). An image of the photographic film was captured and quantified with QuantityOne software (Bio-Rad), and the compound concentrations sufficient to reduce the accumulation of viral DNA by 50% (EC 50 ) were interpolated from the experimental data.
(iv) DNA hybridization assays for HHV-8. Test compounds were diluted in duplicate wells of a 96-well plate, with the highest final concentration being 20 M. BCBL-1 cells were induced to undergo a lytic infection by the addition of phorbol 12-myristate 13-acetate (Promega, Madison, WI) at a final concentration of 100 ng/ml, and 2 ϫ 10 4 cells were added to each well in the plate. Cells were incubated for 7 days at 37°C in a humidified CO 2 incubator, and then total DNA was prepared with a Wizard SV 96-well purification kit (Promega). Viral DNA was quantified by real-time PCR using forward primer 5=-TTC CCC AGA TAC ACG ACA GAA TC-3=, reverse primer 5=-CGG AGC GCA GGC TAC CT-3=, and probe 5=-FAM CCT ACG TGT TCG TCG AC TAMRA-3= (where FAM is 6-carboxyfluorescein and TAMRA is 6-carboxytetramethylrhodamine). Plasmid pMP218 containing a DNA sequence corresponding to nucleotides 14120 to 14182 (accession number AF148805.2) was used to provide absolute quantification of viral DNA. Compound concentrations sufficient to reduce the genome copy number by 50% were calculated from the experimental data.
Cytotoxicity assays. Every antiviral assay included a parallel cytotoxicity assay with the same cells used for each virus, the same cell number, the same drug concentrations, and the same incubation times to provide the same drug exposure. To ensure that the cytotoxicity of all compounds could be compared directly, we also performed a standard neutral red uptake cytotoxicity assay for all compounds in confluent HFF cells with a 7-day incubation period.
(i) Neutral red uptake cytotoxicity assays. Each compound was evaluated in a standard cytotoxicity assay by standard methods (21) . Briefly, HFF cells were seeded into 96-well tissue culture plates at a 2.5 ϫ 10 4 cells/well in standard tissue culture medium. After 24 h of incubation, medium was replaced with maintenance cell culture medium, compounds were added to the first row, and then 5-fold serial dilutions were used to generate a series of compound concentrations with a maximum of 300 M. Assay plates were incubated for 7 days, 100 l of a 0.66-mg/ml neutral red solution in PBS was added to each well, and the plates were incubated for 1 h. The stain was then removed, the plates were rinsed with PBS, and the dye internalized by viable cells was solubilized in PBS supplemented with 50% ethanol and 1% glacial acetic acid. The optical density was then determined at 550 nm, and 50% cytotoxic concentration (CC 50 ) values were interpolated from the experimental data.
For all plaque reduction assays in HFF cells, neutral red cytotoxicity assays were performed on a parallel set of 6-well plates containing uninfected HFF cells that received the same compound concentrations used for the antiviral assays. The cytotoxicity plates were removed from the incubator on the same day as each antiviral assay, and the cell monolayer was stained for 6 h with 2 ml of a neutral red solution at a concentration of 0.165 mg/ml in PBS. The dye was then removed, residual dye was rinsed from the cells with PBS, and cell monolayers were visually inspected for any signs of toxicity. The cytotoxicity assay with Vero cells was performed with drug concentrations ranging from 1 M to 1 mM. The cell viability was determined using a CellTiter 96 Aqueous One Solution cell proliferation assay (Promega) according to the manufacturer's instructions. (ii) Cytotoxicity in lymphocyte assays. Cell viability in all assays with lymphocytes was assessed with a CellTiter-Glo luminescent cell viability assay (Promega) by established methods (22) . Briefly, assay plates were incubated at ambient temperature for 30 min, and then 50 l of CellTiter-Glo reagent was added to each well and the contents of the plates were mixed for 2 min on an orbital shaker to lyse the cells. Plates were then incubated for an additional 10 min at ambient temperature, and the luminescence was quantified on a luminometer. Standard methods were used to calculate the drug concentrations that inhibited the proliferation of Akata, HSB-2, BCLB-1, or Molt-3 cells by 50% (CC 50 ).
(iii) Cell proliferation assays. The inhibition of HFF cell proliferation was used to refine estimates of cytotoxicity for some compounds and was performed according to a standard procedure used in the laboratory (24) . Cells were seeded at a low density into six-well plates using 2.5 ϫ 10 4 cells/well and standard culture medium. After 24 h, the medium was aspirated, compound solutions with a range of compound concentrations in the growth medium starting at 300 M were prepared, and compound at each concentration was added to duplicate wells. The plates were incubated for 72 h at 37°C, and the cells were then dislodged with trypsin and counted on a Beckman Coulter Counter. Compound concentrations that reduced cell proliferation by 50% were interpolated from the experimental data.
RESULTS

Antiviral activity against HSV-1, HSV-2, and VZV.
A series of 18 monohydroxymethyl methylenecyclopropane nucleoside compounds was synthesized and characterized as described above and in the supplemental material. Each of the compounds was evaluated against the alphaherpesviruses by plaque reduction assays, and their antiviral activities are shown in Tables 1 and 2 . Although neither CPV nor the monohydroxymethyl analog (synguanol) has been reported to have any appreciable antiviral activity against these viruses (13, 17) , some analogs with ether substituents at the 6 position did exhibit much better antiviral activity against the alphaherpesviruses. Little activity against HSV-1 was seen with the methyl ester (compound 2a), but longer alkyl esters exhibited good antiviral activity against HSV-1, with the optimal number of carbon atoms being about 2 to 4 (compounds 2b, 2c, and 2e). Reduced activity was observed with compounds with 5 or more carbon atoms (compounds 2f to 2j) or with the addition of a double bond (compound 2d). Some of the analogues were also tested against HSV-1 in Vero cells and were clearly more effective than CPV (Fig. 2) . While CPV was not very active, the new compounds showed good activity while showing a lack of cytotoxicity at the concentrations tested. A similar trend was observed against HSV-2, although the compounds were typically less active. Many of these analogs were also active against VZV, although the activity was less dependent on the size of the alkyl group. For the thioether series, a similar pattern of activity was observed (Table 2) . Little activity against HSV-1 was observed with the methyl derivative (compound 3a), but improved efficacy was apparent for compounds with three carbon atoms (compounds 3b and 3c). As with the ether series, the compounds were slightly less active against HSV-2. Some of these analogs also had good activity against VZV, and like the ether series, activity was less dependent on the size of the alkyl groups. The new analogs were also well tolerated in primary HFF cells, and only compound 3h exhibited an EC 50 of Ͻ300 M in the neutral red cytotoxicity assay. These data taken together indicate that the addition of short-chain ether or thioether substituents at position 6 improves the antiviral activity against the alphaherpesviruses.
Antiviral activity against HCMV and MCMV. The best antiviral activity for CPV is against HCMV (12) , and all the analogs described here were highly active against this virus (Tables 1 and  2 ). Few, if any, differences in the antiviral activity against HCMV were observed, and the EC 50 s were generally indistinguishable from those of synguanol and CPV. The analogs were also generally effective against MCMV, and all were more potent than GCV. Thus, the addition of ether and thioether substituents can improve the activity of the compounds against the alphaherpesviruses but allows them to retain good antiviral activity against HCMV.
Antiviral activity against EBV and HHV-8. All the thioether analogs were active against EBV with EC 50 s that were similar to the EC 50 of synguanol (Table 3) . Similar effects were observed with the thioether derivatives (Table 2) , although antiviral activity was reduced with alkyl groups containing 6 or 7 carbon atoms (compounds 3g and 3h). The replication of HHV-8 was also inhibited by each of the ether analogs, and some appeared to be more potent than CPV (Table 3) . Most of the thioether analogs were also active against HHV-8, although no activity was observed with the analog containing the largest substituent (compound 3h). Each of the compounds was generally well tolerated by lymphocyte cells at concentrations below 20 M, with representative data shown in Table 3 for Akata cells.
Antiviral activity against HHV-6A and HHV-6B. Both variants of HHV-6 are betaherpesviruses like HCMV and have also been reported to be highly susceptible to CPV (13) . The addition of 6-alkoxy substitutions (Table 3) did not result in large changes in the efficacy of the compounds against these viruses, although ethers with three or more carbon atoms tended to have EC 50 s lower than the EC 50 of the methyl ether (compound 2a). All of the analogs had activity against HHV-6B that was superior to that of CDV, with the exception of the analog with a benzyl substitution (compound 2j). In the thioether series (Table 4) , antiviral activity tended to increase with chain length up to about 5 carbon atoms (compound 2f). All the molecules with alkyl groups of less than 6 carbon atoms were more potent against HHV-6B than the CDV control. These data suggest that the antiviral activities of these compounds against both variants of HHV-6 were similar to those against HCMV, in that they were fairly tolerant to the 6-ester substitutions up to about 5 carbon atoms in length.
Efficacy against drug-resistant isolates of HSV and HCMV. Representative compounds were evaluated against drug-resistant isolates of HSV and HCMV to see if they might be useful against resistant infections. The efficacy of one representative compound, 3c, was evaluated against thymidine kinase (TK)-negative isolates of HSV-1 and HSV-2 to determine whether the compounds might require this enzyme for their initial phosphorylation using ACV and CDV as controls ( Table 5 ). As expected, both TK-negative mutants were completely resistant to ACV. In contrast, compound 3c remained effective against the resistant isolates, with EC 50 s being elevated between 0.66-and 1.9-fold, and the EC 50 s were comparable to the EC 50 observed for the CDV-treated negative control (2.3-fold). Thus, the TK encoded by this virus does not appear to be required for the antiviral activity of these compounds. A similar study was performed with compound 3a against clinical isolates of HCMV that are resistant to GCV using CDV as a control (Table 6 ). Isolates C8805/37-1-1 and 759 R D100 were highly resistant to GCV and were also 5-to 8-fold resistant to compound 3a compared to AD169, consistent with previous reports showing that the UL97 kinase is also responsible for phosphorylating synguanol (25) and cyclopropavir (13) .
Cytotoxicity of methylenecyclopropane analogs. To ensure the specificity of the antiviral activity, the cytotoxicity of this set of compounds was evaluated concurrently with the determination of antiviral activity. The effect of three representative compounds on the proliferation of subconfluent HFF cells was also determined, and in our hands this effect is a much more sensitive indicator of cytotoxicity ( Table 7) . Each of the compounds tested was less toxic than the fialuridine (FIAU) control in this assay. Of the three compounds tested, compound 3a had the highest CC 50 value, although in this study the CC 50 was still less than the value for GCV. The CC 50 values for the remaining two compounds were comparable to the CC 50 for CPV, and all CC 50 s were less than the CC 50 for GCV.
DISCUSSION
The morbidity and mortality associated with herpesvirus infections in immunocompromised hosts have been significantly reduced by effective therapeutic agents. The greatest strides have been made toward the control of HSV and, to a lesser extent, VZV infections; however, therapies for HCMV are associated with dose-limiting toxicities that restrict the usefulness of compounds such as ganciclovir and foscarnet. EBV, HHV-6A, HHV-6B, HHV-7, or HHV-8 infections are also underserved by the current armamentarium of compounds. Ideally, a single drug might be used in prophylactic therapy to suppress infections of all the human herpesviruses, since immunocompromised hosts are at elevated risk of infection with all of them. The broad-spectrum antiviral activity exhibited by synguanol and related analogs indicated that some analogs in this series might be effective against most, if not all, of these viruses. The compounds described here were designed to yield a more complete set of compounds to help define structure-activity relationships for each of the viruses and help identify the molecules with the best spectrum of antiviral activity. The lead compound of methylenecyclopropane analogs, cyclopropavir (CPV), was evaluated against all the human herpesviruses except HHV-7 and was active against CMV, HHV-6A, HHV-6B, and HHV-8 (13) . For CMV, this compound was shown to require the UL97 kinase for its antiviral activity and retained activity against most GCV-resistant isolates and clinical isolates. It was also effective in vivo in two animal models of human CMV infection (14) . Other (Z)-and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines also have activity against both CMV and MCMV (12) . Another class of halogenated methylenecyclopropane analogs was identified, including the (Z)-and (E)-[2-fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, which exhibited activity against CMV, HSV, VZV, and EBV (26) (27) (28) . Additionally, some (Z)-and (E)-9-([(2-fluoromethyl-2-hydroxymethyl)-cyclopropylidene]methyl) adenine and -guanine analogs were modestly effective against CMV (29, 30) . These results were extended to include (Z)-and (E)-2-(1,2-dihydroxyethyl)methylenecyclopropane analogues of 2=-deoxyadenosine and 2=-deoxyguanosine, some of which were active against CMV, MCMV, and EBV (31) .
Further studies showed that phosphonate analogs of CPV phosphates also showed antiviral activity against CMV and retained activity against GCV-resistant isolates with mutations in the UL97 kinase, as would be expected for these monophosphate analogs (32) . Phosphoralaninate pronucleotides of pyrimidine methylenecyclopropane analogues also exhibited some antiviral activity against CMV or EBV (33-35). Valine esters of cyclopropavir also had improved oral bioavailability and represent an important step in the preparation of a formulation for clinical studies (36) . More recent studies have identified additional analogs with a broader spectrum of antiviral activity that includes HHV-6 as well as HHV-8 (20) .
Initial reports describing the antiviral activity of synguanol and related analogs reported antiviral activity for some of the compounds against many viruses, including HSV-1, HSV-2, HCMV, MCMV, EBV, VZV, HHV-6A, HHV-6B, and HHV-8 (15, 19, 37, 38) . These data were compiled and summarized in a review article by Zemlicka that serves as a convenient means to compare data from the series of compounds described here with results published previously for a small subset of these compounds using the numbering system in this publication (10) . The antiviral activities reported previously for synguanol and its methyl, propyl, pentyl, and allyl ether analogs against HSV-1 and HCMV were within the standard deviation values shown in Table 1 , where available. The single exception was for the propyl ether, compound 2c, where the previously reported value against HCMV was 2 M, in comparison to a value of 1.6 Ϯ 0.2 M in Table 1 . The efficacy of compound 3b against HSV-1 reported previously was 1 M, in comparison to a value of 8.6 Ϯ 3.6 M in Table 2 , and the efficacy of compound 3b against HCMV reported previously was 3 M, in comparison to a value of 0.74 Ϯ 0.03 M in Table 2 . Data for HSV-2 were determined in an enzyme-linked immunosorbent assay and are not directly comparable to the plaque reduction data presented here. Previously reported values for compounds 2c, 2d, and 2f against HHV-6B were all about 1 M and are slightly lower than the values reported in Table 3 , but these were generated in cord blood lymphocytes that in our experience yield lower values for most compounds. The reported efficacies for these same compounds against HHV-8 were also within the standard deviation values shown in Table 3 , with the exception of compound 2d, which was previously found to be 2.9 M but for which the value in Table 3 is 2.2 Ϯ 0.2 M. Previously reported values for compound 3b against HHV-6B also agreed well with the values in Table 4 , but the efficacy against HHV-8 was previously found to be 3.7 M, in comparison to a value of 1.9 Ϯ 0.4 M in Table 4 . Overall, the data presented here were very consistent with the values reported for this subset of compounds and reflect the reproducibility of the synthesis and evaluation of these molecules. A major objective of these studies was to identify compounds with improved efficacy against HCMV, HHV-6, and HHV-8. These studies did identify compounds with modestly improved efficacy against these viruses, such as compound 2f against HHV-6B and HHV-8. Much greater improvements in efficacy were observed against the alphaherpesviruses. For example, the antiviral activity of compound 2c against HSV-1 and VZV was increased by 5-and 8-fold, respectively. This is important, because all these infections are problematic in immunosuppressed patients and compounds with broad-spectrum antiviral activity would be particularly well suited to suppress these infections.
